David P. Snow

Biography

David Snow has served as our Chief Commercial Officer since September 2015. At Radius, he is accountable for commercial launches, strategy and P&L management, as well as leading the cross-functional late-stage development team responsible for progressing Phase III and Phase IV portfolio programs. David has more than 25 years of management, sales and marketing experience across numerous leadership roles and therapeutic areas. Prior to joining Radius, David was President of AstraZeneca’s (AZ) China organization from January 2012 to December 2014. Under his leadership, China became AZ’s second-largest and fastest-growing business with $2 billion in total sales and 25 percent growth rate in 2014. David was responsible for the successful launches of Onglyza®, Byetta® and Brilinta® during his China tenure. Before this, he was Vice President of one of two U.S. business units achieving $4 billion in 2011 sales. David also worked as Global Marketing Vice President, Cardiovascular, leading the Brilinta/Brilique™ Global Brand Team during its prelaunch phase. He came to AZ in 2001 to lead the U.S. Cardiovascular team launching Toprol-XL® for heart failure, which achieved a 48 percent increase in sales and became the No. 1 prescribed cardiology brand. Prior to AZ, David was Senior Director of U.S. CNS marketing at Bristol-Myers Squibb (BMS) in Princeton, N.J. While at BMS, David worked in global marketing launching Avapro®/Avalide® brands. David served on the Research and Development-based Pharmaceutical Association Committee industry association board in China for several years. David earned a B.S. in Business Administration from Auburn University and an M.B.A. from New York University’s Stern School of Business. 

Research Interest

Business Development, strategy and P&L management